Contact
searchSearch
HMP Global

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Nasal Polyps Topic Center

Featured Article

News
Eosinophilic Esophagitis Symptoms Improved by Monoclonal Antibody Therapy
02/25/2022
Patients receiving treatment with a monoclonal antibody for asthma, atopic dermatitis, and nasal polyps also saw improvements in concomitant eosinophilic esophagitis symptoms, according to a retrospective chart review.
Patients receiving treatment with a monoclonal antibody for asthma, atopic dermatitis, and nasal polyps also saw improvements in concomitant eosinophilic esophagitis symptoms, according to a retrospective chart review.
Patients receiving treatment...
02/25/2022
First Report Managed Care
News
Dupilumab Improves Symptoms in Patients With Severe CRSwNP and Comorbid Asthma
10/27/2021
“In the difficult-to-treat population of patients with [chronic rhinosinusitis with nasal polyps] with comorbid asthma, the results presented here illustrate that dupilumab as an add-on to the standard-of-care mometasone furoate nasal spray...
“In the difficult-to-treat population of patients with [chronic rhinosinusitis with nasal polyps] with comorbid asthma, the results presented here illustrate that dupilumab as an add-on to the standard-of-care mometasone furoate nasal spray...
“In the difficult-to-treat...
10/27/2021
First Report Managed Care
Headshot of Peter Lio, MD, FAAD, on a blue background underneath the PopHealth Perspectives logo.
Podcasts
Addressing Unmet Needs in Patients With Type 2 Inflammatory Conditions
09/28/2021
Peter Lio, MD, FAAD, clinical assistant professor of dermatology & pediatrics, Northwestern University Feinberg School of Medicine, and founding director, Chicago Integrative Eczema Center, discusses the common challenges associated with...
Peter Lio, MD, FAAD, clinical assistant professor of dermatology & pediatrics, Northwestern University Feinberg School of Medicine, and founding director, Chicago Integrative Eczema Center, discusses the common challenges associated with...
Peter Lio, MD, FAAD, clinical...
09/28/2021
First Report Managed Care
News
Dupilumab offers relief for severe chronic rhinosinusitis with nasal polyps
09/27/2019
Dupilumab reduces polyp size and symptom severity in patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP), according to results from two randomized clinical trials. ...
Dupilumab reduces polyp size and symptom severity in patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP), according to results from two randomized clinical trials. ...
Dupilumab reduces polyp size and...
09/27/2019
First Report Managed Care
News
Lower QoL Among Patients With Chronic Rhinosinusitis With Nasal Polyps
07/29/2019
Recent research found that patients with chronic rhinosinusitis with nasal polyps experience a significantly lower health-related quality of life.
Recent research found that patients with chronic rhinosinusitis with nasal polyps experience a significantly lower health-related quality of life.
Recent research found that...
07/29/2019
First Report Managed Care
News
First Treatment Approved for Chronic Rhinosinusitis With Nasal Polyps
06/26/2019
Dupixent (dupilumab; Regeneron Pharmaceuticals and Sanofi), is the first treatment approved by the FDA for the treatment of inadequately controlled chronic rhinosinusitis with nasal polyps.
Dupixent (dupilumab; Regeneron Pharmaceuticals and Sanofi), is the first treatment approved by the FDA for the treatment of inadequately controlled chronic rhinosinusitis with nasal polyps.
Dupixent (dupilumab; Regeneron...
06/26/2019
First Report Managed Care
Chronic Rhinosinusitis With Nasal Polyps (CRSwNP): The Challenge of Long-term Control

Newsfeed

News
Eosinophilic Esophagitis Symptoms Improved by Monoclonal Antibody Therapy
02/25/2022
Patients receiving treatment with a monoclonal antibody for asthma, atopic dermatitis, and nasal polyps also saw improvements in concomitant eosinophilic esophagitis symptoms, according to a retrospective chart review.
Patients receiving treatment with a monoclonal antibody for asthma, atopic dermatitis, and nasal polyps also saw improvements in concomitant eosinophilic esophagitis symptoms, according to a retrospective chart review.
Patients receiving treatment...
02/25/2022
First Report Managed Care
News
Dupilumab Improves Symptoms in Patients With Severe CRSwNP and Comorbid Asthma
10/27/2021
“In the difficult-to-treat population of patients with [chronic rhinosinusitis with nasal polyps] with comorbid asthma, the results presented here illustrate that dupilumab as an add-on to the standard-of-care mometasone furoate nasal spray...
“In the difficult-to-treat population of patients with [chronic rhinosinusitis with nasal polyps] with comorbid asthma, the results presented here illustrate that dupilumab as an add-on to the standard-of-care mometasone furoate nasal spray...
“In the difficult-to-treat...
10/27/2021
First Report Managed Care
News
Dupilumab offers relief for severe chronic rhinosinusitis with nasal polyps
09/27/2019
Dupilumab reduces polyp size and symptom severity in patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP), according to results from two randomized clinical trials. ...
Dupilumab reduces polyp size and symptom severity in patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP), according to results from two randomized clinical trials. ...
Dupilumab reduces polyp size and...
09/27/2019
First Report Managed Care
News
Lower QoL Among Patients With Chronic Rhinosinusitis With Nasal Polyps
07/29/2019
Recent research found that patients with chronic rhinosinusitis with nasal polyps experience a significantly lower health-related quality of life.
Recent research found that patients with chronic rhinosinusitis with nasal polyps experience a significantly lower health-related quality of life.
Recent research found that...
07/29/2019
First Report Managed Care
News
First Treatment Approved for Chronic Rhinosinusitis With Nasal Polyps
06/26/2019
Dupixent (dupilumab; Regeneron Pharmaceuticals and Sanofi), is the first treatment approved by the FDA for the treatment of inadequately controlled chronic rhinosinusitis with nasal polyps.
Dupixent (dupilumab; Regeneron Pharmaceuticals and Sanofi), is the first treatment approved by the FDA for the treatment of inadequately controlled chronic rhinosinusitis with nasal polyps.
Dupixent (dupilumab; Regeneron...
06/26/2019
First Report Managed Care
News
Using Deep Learning to Measure MS-Specific Brain Damage Beyond Aging
11/11/2024
A new study published in Neurology aimed to differentiate age-related brain changes from multiple sclerosis (MS)-specific neurodegeneration using MRI.
A new study published in Neurology aimed to differentiate age-related brain changes from multiple sclerosis (MS)-specific neurodegeneration using MRI.
A new study published in...
11/11/2024
First Report Managed Care
News
Adverse Event Data Suggest Selective β1-blockers Pose Asthma Risk
11/11/2024
The risks of asthma and asthma-like adverse events appear to be higher with selective β1-blockers than with nonselective blockers and α- and β-blockers.
The risks of asthma and asthma-like adverse events appear to be higher with selective β1-blockers than with nonselective blockers and α- and β-blockers.
The risks of asthma and...
11/11/2024
First Report Managed Care
News
RNAi Therapies Offer New Hope for Patients With Hereditary Transthyretin Amyloidosis
11/08/2024
RNA interference (RNAi)-based treatments for hereditary transthyretin amyloidosis (ATTR) have shown remarkable promise, offering new hope for patients with this rare but devastating genetic disorder.
RNA interference (RNAi)-based treatments for hereditary transthyretin amyloidosis (ATTR) have shown remarkable promise, offering new hope for patients with this rare but devastating genetic disorder.
RNA interference (RNAi)-based...
11/08/2024
First Report Managed Care
News
Revolutionary Single-Dose Gene Therapy Offers New Hope for Adults with Hemophilia B
11/08/2024
A groundbreaking gene therapy for hemophilia B has shown remarkable success in reducing bleeding episodes and improving the quality of life for adult patients, according to a recent international phase III clinical trial.
A groundbreaking gene therapy for hemophilia B has shown remarkable success in reducing bleeding episodes and improving the quality of life for adult patients, according to a recent international phase III clinical trial.
A groundbreaking gene therapy...
11/08/2024
First Report Managed Care
News
Real-World Evidence Supports Efficacy and Safety of Selexipag in Patients With Pulmonary Arterial Hypertension
11/07/2024
Real-world data shows selexipag effectively improves functional class and risk category outcomes in patients with pulmonary arterial hypertension, regardless of maintenance dose.
Real-world data shows selexipag effectively improves functional class and risk category outcomes in patients with pulmonary arterial hypertension, regardless of maintenance dose.
Real-world data shows selexipag...
11/07/2024
First Report Managed Care
News
Clinical Predictors of One-Year Seizure Freedom After SLAH
11/06/2024
A study published in Annals of Clinical and Translational Neurology aimed to predict 1-year seizure freedom for patients undergoing stereotactic laser amygdalohippocampotomy (SLAH) for mesial temporal lobe epilepsy (MTLE) using a set of...
A study published in Annals of Clinical and Translational Neurology aimed to predict 1-year seizure freedom for patients undergoing stereotactic laser amygdalohippocampotomy (SLAH) for mesial temporal lobe epilepsy (MTLE) using a set of...
A study published in Annals of...
11/06/2024
First Report Managed Care
News
Efficacy and Outcomes of Neoadjuvant Immunotherapy in Lung Cancer
11/05/2024
A meta-analysis of 43 studies suggests that neoadjuvant chemoimmunotherapy may benefit patients with resectable NSCLC and low tumor PD-L1 levels for event-free survival, showing superior outcomes compared to neoadjuvant chemotherapy.
A meta-analysis of 43 studies suggests that neoadjuvant chemoimmunotherapy may benefit patients with resectable NSCLC and low tumor PD-L1 levels for event-free survival, showing superior outcomes compared to neoadjuvant chemotherapy.
A meta-analysis of 43 studies...
11/05/2024
First Report Managed Care
News
FDA Grants Accelerated Approval for Asciminib as First-Line Treatment in Ph+CML-CP
11/01/2024
Novartis received accelerated approval by the US Food and Drug Administration (FDA) for asciminib, a medication for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+CML-CP).
Novartis received accelerated approval by the US Food and Drug Administration (FDA) for asciminib, a medication for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+CML-CP).
Novartis received accelerated...
11/01/2024
First Report Managed Care
News
HHS Faces Legal Action From 10 Hospitals Over 2023 Medicare Advantage Rule and Reimbursement Calculations
10/30/2024
Ten hospitals sued the US Department of Health and Human Services (HHS), claiming that they were underpaid Medicare reimbursements for serving low-income patients.
Ten hospitals sued the US Department of Health and Human Services (HHS), claiming that they were underpaid Medicare reimbursements for serving low-income patients.
Ten hospitals sued the US...
10/30/2024
First Report Managed Care
News
Impact of Immune Checkpoint Inhibitors on Multiple Sclerosis Treatment Outcomes
10/29/2024
Relapses and progression of multiple sclerosis were rare in patients treated with immune checkpoint inhibitors, according to a study presented at the American Academy of Neurology 2024 Annual Meeting.
Relapses and progression of multiple sclerosis were rare in patients treated with immune checkpoint inhibitors, according to a study presented at the American Academy of Neurology 2024 Annual Meeting.
Relapses and progression of...
10/29/2024
First Report Managed Care

Advertisement

Recent Articles

News
Eosinophilic Esophagitis Symptoms Improved by Monoclonal Antibody Therapy
02/25/2022
Patients receiving treatment with a monoclonal antibody for asthma, atopic dermatitis, and nasal polyps also saw improvements in concomitant eosinophilic esophagitis symptoms, according to a retrospective chart review.
Patients receiving treatment with a monoclonal antibody for asthma, atopic dermatitis, and nasal polyps also saw improvements in concomitant eosinophilic esophagitis symptoms, according to a retrospective chart review.
Patients receiving treatment...
02/25/2022
First Report Managed Care
News
Dupilumab Improves Symptoms in Patients With Severe CRSwNP and Comorbid Asthma
10/27/2021
“In the difficult-to-treat population of patients with [chronic rhinosinusitis with nasal polyps] with comorbid asthma, the results presented here illustrate that dupilumab as an add-on to the standard-of-care mometasone furoate nasal spray...
“In the difficult-to-treat population of patients with [chronic rhinosinusitis with nasal polyps] with comorbid asthma, the results presented here illustrate that dupilumab as an add-on to the standard-of-care mometasone furoate nasal spray...
“In the difficult-to-treat...
10/27/2021
First Report Managed Care
Headshot of Peter Lio, MD, FAAD, on a blue background underneath the PopHealth Perspectives logo.
Podcasts
Addressing Unmet Needs in Patients With Type 2 Inflammatory Conditions
09/28/2021
Peter Lio, MD, FAAD, clinical assistant professor of dermatology & pediatrics, Northwestern University Feinberg School of Medicine, and founding director, Chicago Integrative Eczema Center, discusses the common challenges associated with...
Peter Lio, MD, FAAD, clinical assistant professor of dermatology & pediatrics, Northwestern University Feinberg School of Medicine, and founding director, Chicago Integrative Eczema Center, discusses the common challenges associated with...
Peter Lio, MD, FAAD, clinical...
09/28/2021
First Report Managed Care
News
Dupilumab offers relief for severe chronic rhinosinusitis with nasal polyps
09/27/2019
Dupilumab reduces polyp size and symptom severity in patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP), according to results from two randomized clinical trials. ...
Dupilumab reduces polyp size and symptom severity in patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP), according to results from two randomized clinical trials. ...
Dupilumab reduces polyp size and...
09/27/2019
First Report Managed Care
News
Lower QoL Among Patients With Chronic Rhinosinusitis With Nasal Polyps
07/29/2019
Recent research found that patients with chronic rhinosinusitis with nasal polyps experience a significantly lower health-related quality of life.
Recent research found that patients with chronic rhinosinusitis with nasal polyps experience a significantly lower health-related quality of life.
Recent research found that...
07/29/2019
First Report Managed Care

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement